Ingenix is an AI and biology company built around the question of what it would take for AI to truly understand biology. Its Biological Reasoning Engine is built on Modality Fusion, a novel AI architecture that integrates best-in-class models across modalities and biological scales, then reasons across their representations directly. The engine is built for translational and clinical R&D decisions.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €13 M | Jun, 2026 | seed |
Industries
Frequently Asked Questions
Where is Ingenix located?
Ingenix is located in Warsaw, Poland.
What industries does Ingenix operate in?
Ingenix operates in the following industries: artificial intelligence, biotechnology, drug development.
When was Ingenix founded?
Ingenix was founded on 2026-06-03.
How much total funding has Ingenix raised?
Ingenix has raised a total of $13,000,000.
Who are the investors in Ingenix?
The investors in Ingenix are: Sofinnova Partners, Inovo VC, OTB VC.
What is Ingenix and what does it do?
Ingenix is a biotechnology company that provides a proprietary multimodal and multiscale generative AI co-pilot designed to simulate clinical trials on digital twins to support drug development.
How does the Ingenix AI platform work?
Ingenix utilizes an AI architecture called Modality Fusion, which integrates biological and medical knowledge across various data types, including text, bioimaging, 3D structures, and sequences, to reason across molecular, cellular, and population levels.
Who are the primary customers for Ingenix?
Ingenix primarily serves pharmaceutical companies and drug development organizations by helping them predict trial outcomes, endpoints, and potential adverse events.
Who founded Ingenix?
Ingenix was founded in 2023 by Piotr Surma and Adam Dancewicz, the former founders of the AI startup Applica.
How does Ingenix address challenges in the pharmaceutical industry?
Ingenix aims to reduce the high failure rates and costs associated with clinical trials by providing a Biological Reasoning Engine that allows scientists to simulate trials and make more informed R&D decisions.